New Formulations of Antipsychotic Abilify Introduced

(February 7, 2006) - Bristol-Myers Squibb Co. reports that its schizophrenia drug Abilify will now be available in two new formulations: a 2 milligram tablet and an oral solution that does not require refrigeration.

advertisement

Until now the Abilify tablets have been available in several higher dose levels. The company said the lower, 2 milligram dose will allow physicians to bring patients to their optimum dose more easily.

The nonrefrigerated Abilify oral solution will allow greater convenience for adult patients who have difficulty swallowing tablets, the company said. Bristol-Myers is partnering with Otsuka Pharmaceutical Co. Ltd. of Japan to develop and commercialize the drug in the U.S. and Europe.

Source: Bristol-Myers Press Release

Last updated: 2/06

top ~ next ~ news table of contents ~ send page to a friend

We subscribe to the HONcode principles. Verify here.